Baxter International has finally put a price-fixing lawsuit against the health care giant behind as a federal judge finalized the company’s $64 million settlement.
Reports say the company’s offer puts the total amount of damages recovered by the plaintiffs in the case to $128 million.
The class action sued accused Baxter and other companies of colluding to fix the price of a blood plasma derivative, collaborating to restrict its supply to hike prices between 2003 and 2009.
Among the companies that have settled include CSL Limited, CSL Behring, CSL Plasma, and the Plasma Protein Therapeutics Association. Those firms similarly settled for $64 million, an offer that was finalized earlier this yea by US District Judge Joan B. Gottschall.
Full Content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Justice Department Moves to End NCAA Transfer Rule
May 30, 2024 by
CPI
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI